TBVI in its business model considers the need to:

  • innovate and diversify the TB vaccine and biomarker pipeline;
  • early identify and support the most promising vaccine candidates through clinical development;
  • ensure acceptability, access and affordability of new TB vaccines for the end user;
  • accelerate TB vaccine R&D through  partnership;
  • deliver through TBVI, key service support to R&D partners including neutral and non-biased technical advice for clinical product development and portfolio priority selection decisions for funders;
  • provide efficient and effective financial management and oversight;
  • generate both social and economic returns for investors.

Elements of the business model:

  • accelerating R&D through partnership:
    • consortium approach for concept and idea generation; knowledge development, exchange; and collaborative research;
    • partner with industry;
    • support the development of and participate in global networks and partnerships;
  • a portfolio management approach for entry of candidates into the pipeline and selection of candidates for support for preclinical and clinical development;
  • promote innovation and ensure access;
    • ownership and IP rest with research and vaccine development partners;
    • upstream agreements with research partners and vaccine developers to promote access and affordability of the vaccine for the end user;
  • provision of essential services to support R&D activities of partners;
    • project identification, design and development;
    • project management;
    • resource mobilisation;
    • knowledge development and exchange, and networking;
    • technical support for product and clinical development.